Dr. Wierda Discusses the Role of Ibrutinib in CLL
William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia.
William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).
Considering all the progress being made with novel therapies in this disease, ibrutinib remains a vital part of frontline treatment for patients with CLL, says Wierda.
Currently, trials investigating dosing are aiming to determine whether a lower dose of ibrutinib may be as effective or better tolerated than 420 mg.
